CN113811530A - 作为糜酶抑制剂的嘧啶酮类化合物及其应用 - Google Patents

作为糜酶抑制剂的嘧啶酮类化合物及其应用 Download PDF

Info

Publication number
CN113811530A
CN113811530A CN202080035154.8A CN202080035154A CN113811530A CN 113811530 A CN113811530 A CN 113811530A CN 202080035154 A CN202080035154 A CN 202080035154A CN 113811530 A CN113811530 A CN 113811530A
Authority
CN
China
Prior art keywords
compound
isomer
mixture
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080035154.8A
Other languages
English (en)
Other versions
CN113811530B (zh
Inventor
颜小兵
丁照中
蔡亚仙
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN113811530A publication Critical patent/CN113811530A/zh
Application granted granted Critical
Publication of CN113811530B publication Critical patent/CN113811530B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一类具有嘧啶酮结构的作为糜酶(chymase)抑制剂药物的化合物，具体公开了式(I)所示化合物、其药学上可接受的盐及其异构体，以及包含它们的药物组合物。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN202080035154.8A 2019-07-03 2020-07-03 作为糜酶抑制剂的嘧啶酮类化合物及其应用 Active CN113811530B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019105972055 2019-07-03
CN201910597205 2019-07-03
CN202010402394 2020-05-13
CN2020104023949 2020-05-13
PCT/CN2020/100127 WO2021000933A1 (zh) 2019-07-03 2020-07-03 作为糜酶抑制剂的嘧啶酮类化合物及其应用

Publications (2)

Publication Number Publication Date
CN113811530A true CN113811530A (zh) 2021-12-17
CN113811530B CN113811530B (zh) 2022-07-19

Family

ID=74100311

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080035154.8A Active CN113811530B (zh) 2019-07-03 2020-07-03 作为糜酶抑制剂的嘧啶酮类化合物及其应用

Country Status (2)

Country Link
CN (1) CN113811530B (zh)
WO (1) WO2021000933A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022135534A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 取代的含氮双环化合物及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101505752A (zh) * 2006-06-23 2009-08-12 史密丝克莱恩比彻姆公司 脯氨酸羟化酶抑制剂
CN104395310A (zh) * 2012-05-09 2015-03-04 拜耳药业股份公司 二环取代尿嘧啶及其用途
CN105873919A (zh) * 2013-11-08 2016-08-17 拜耳医药股份有限公司 作为类糜蛋白酶抑制剂的取代的尿嘧啶
CN105899500A (zh) * 2013-11-08 2016-08-24 拜耳医药股份有限公司 取代的1，2，4-三嗪-3，5-二酮及其作为类糜蛋白酶抑制剂的用途
CN105980381A (zh) * 2013-11-08 2016-09-28 拜耳医药股份有限公司 取代的尿嘧啶及其用途
WO2018114514A1 (de) * 2016-12-20 2018-06-28 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101505752A (zh) * 2006-06-23 2009-08-12 史密丝克莱恩比彻姆公司 脯氨酸羟化酶抑制剂
CN104395310A (zh) * 2012-05-09 2015-03-04 拜耳药业股份公司 二环取代尿嘧啶及其用途
CN105873919A (zh) * 2013-11-08 2016-08-17 拜耳医药股份有限公司 作为类糜蛋白酶抑制剂的取代的尿嘧啶
CN105899500A (zh) * 2013-11-08 2016-08-24 拜耳医药股份有限公司 取代的1，2，4-三嗪-3，5-二酮及其作为类糜蛋白酶抑制剂的用途
CN105980381A (zh) * 2013-11-08 2016-09-28 拜耳医药股份有限公司 取代的尿嘧啶及其用途
WO2018114514A1 (de) * 2016-12-20 2018-06-28 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AHMAD，S.等: "Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018)", 《EXPERT OPINION ON THERAPEUTIC PATENTS》 *

Also Published As

Publication number Publication date
WO2021000933A1 (zh) 2021-01-07
CN113811530B (zh) 2022-07-19

Similar Documents

Publication Publication Date Title
WO2018137683A1 (zh) 羊毛甾醇前药化合物及其制备方法和应用
WO2021093839A1 (zh) 作为btk抑制剂的吡咯并嘧啶类化合物及其应用
CN114728967A (zh) 作为jak抑制剂的三并杂环类化合物及其应用
WO2022063308A1 (zh) 一类1,7-萘啶类化合物及其应用
CN113227051B (zh) 用于视网膜疾病的化合物
WO2022194221A1 (zh) 呋喃稠环取代的戊二酰亚胺类化合物
CN113811530B (zh) 作为糜酶抑制剂的嘧啶酮类化合物及其应用
WO2022237797A1 (zh) 烷基羧酸化合物及其应用
CN115667258A (zh) 氟代吡咯并吡啶类化合物及其应用
WO2021129817A1 (zh) 具有果糖激酶(khk)抑制作用的嘧啶类化合物
CN112955453B (zh) 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
CN112218871B (zh) 噻吩并[2,3-c]哒嗪-4(1H)-酮类衍生物及其应用
CN114761407A (zh) 作为高选择性ros1抑制剂的化合物及其应用
CN114008046A (zh) 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
WO2022253335A1 (zh) 含磺酰基的芳基类化合物及其应用
WO2022199635A1 (zh) 苄氨基喹唑啉类衍生物
CN113439080B (zh) 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物
CN113825750B (zh) 作为sglt1抑制剂的葡糖苷类衍生物及其应用
CN112752749B (zh) 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物
CN115210230A (zh) 杂环类化合物
CN115515963A (zh) 嘧啶三并环类化合物及其应用
CN115003672A (zh) 喹啉并咪唑类化合物及其应用
JP3229693B2 (ja) ピペラジン誘導体
JP2022540360A (ja) Ｄｎａ－ｐｋ阻害剤としてのキノリン及びシンノリン誘導体
TWI808786B (zh) 酮類衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant